摘要
口腔癌作为国内最常见的头颈部鳞癌类型,其局部晚期患者的治疗通常采用外科手术继以辅助放疗的治疗模式。在过去的10年间,局部晚期口腔癌的治疗进展有限,整体5年生存率小于50%。虽然既往采用新辅助化疗或靶向治疗的临床研究获得了较高的肿瘤缓解率,但未能转化为生存的改善。近年来,随着以免疫检查点抑制剂为代表的免疫治疗在复发转移头颈部鳞癌领域的成功,新辅助免疫治疗成为研究的热点,以注册为目的的随机对照研究正在开展之中。本文针对局部晚期口腔癌新辅助治疗的相关临床研究和治疗进展进行综述。
Oral cavity cancer is the most common type of head and neck squamous cell carcinoma,and patients with locally advanced cancer are mainly treated via surgical resection,followed by adjuvant radiotherapy.However,over the past decade,therapeutic progress in locally advanced oral cavity cancer has been limited,with the overall survival remaining below 50%.Although many studies have reported high tumor response rates with neoadjuvant chemotherapy and targeted therapy,these findings have not translated into enhanced patient survival.Neoadjuvant immunotherapy has become a research hotspot owing to the success of immunotherapy with immune checkpoint inhibitors for relapsed and metastatic head and neck squamous cell carcinoma cases,with many ongoing randomized controlled studies focusing on drug discovery.In this review,we discuss the relevant clinical studies and highlight the therapeutic advancements in neoadjuvant immunotherapy for locally advanced oral cavity cancer.
作者
薛丽琼(综述)
郭晔(审校)
Liqiong Xue;Ye Guo(Department of Oncology,Shanghai East Hospital,School of Medicine,Tongji University,Shanghai 200123,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2024年第19期988-992,共5页
Chinese Journal of Clinical Oncology
基金
上海市浦东新区卫生健康委员卫生科技项目(编号:PW2023A-11)资助。
关键词
口腔癌
新辅助治疗
免疫治疗
病理学缓解
oral cavity cancer
neoadjuvant therapy
immunotherapy
pathological response
作者简介
通信作者:郭晔,pattrickguo@gmail.com;薛丽琼,专业方向为头颈部恶性肿瘤的综合诊治及新药临床研究。E-mail:xlqlily@163.com。
